RTX vs SGMO · P/E 36, rev $88.60B vs rev $57.8M
RTX Corporation (RTX) versus Sangamo Therapeutics Inc (SGMO) — a side-by-side from cached financials, not a winner call.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Sangamo Therapeutics Inc (SGMO) is a biotechnology company listed on NASDAQ.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Latest reported SGMO revenue for 2024-12-31 was $57.8M. Net income was -$97.9M. Revenue was down 67.2% from 2023-12-31 to 2024-12-31. SGMO currently screens at market cap $74.6M.
RTX currently screens at market cap $259.34B and trailing P/E 36.2. SGMO currently screens at market cap $74.6M.
Not investment advice. Open the RTX and SGMO stock pages for the full models.
Not investment advice.